Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of Acthar® in Subjects With Relapsing-remitting Multiple Sclerosis

NCT03126760 is registered in ClinicalTrials.gov with Mallinckrodt ARD LLC as lead sponsor.

NCT NCT03126760
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03126760 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double Blind, Placebo Controlled Parallel Group, Pilot Study to Assess the Efficacy and Safety of Acthar® in Subjects With Relapsing-remitting Multiple Sclerosis
Lead sponsor
Mallinckrodt ARD LLC
Phase
Phase 4
Overall status
Terminated
Start date
May 22, 2017
Completion date
July 14, 2020
Enrollment
35 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, relapsing-remitting